Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regular inhaled corticosteroid versus as-needed budesonide/formoterol in adults with mild asthma
ACTRN12622000232730Phase 4Not yet recruiting
- Sponsor
- Dr John D Brannan
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fluticasone, fluticasone propionate, budesonide + formoterol, budesonide and salbutamol in asthma (3 arms), sponsored by Dr John D Brannan. Primary endpoints: Primary Outcome 1 and Primary Outcome 2. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
fluticasonefluticasone propionatebudesonide + formoterolbudesonidesalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12622000232730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000232730.